115370 Results

People

  1. Ladanyi
    Ladanyi
  2. Motzer
    Motzer
  3. Reuter
    Reuter
  4. Scher
    Scher
  5. Brennan
    Brennan
  6. Giralt
    Giralt
  7. Gonen
    Gonen
  8. Perales
    Perales
  9. Hudis
    Hudis
  10. Jarnagin
    Jarnagin

Groups

  1. Department of Medicine (39030)
  2. GSK Faculty (22466)
  3. Solid Tumor Oncology Division (22055)
  4. Surgery (21246)
  5. Sloan Kettering Institute Faculty (16085)
  6. Survivorship Research (15761)
  7. Center for Hematologic Malignancies (13261)
  8. Hematologic Malignancies, Division of (13086)
  9. Sloan Kettering Institute Postdocs (12935)
  10. Department of Pathology and Laboratory Medicine (12608)
Formats
  1. Journal Article (66747)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3743)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39030)
  2. GSK Faculty (22466)
  3. Solid Tumor Oncology Division (22055)
  4. Surgery (21246)
  5. Sloan Kettering Institute Faculty (16085)
  6. Survivorship Research (15761)

More Groups

People
  1. Marc Ladanyi (1326)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1049)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Engaging older adults living with and after cancer in a research priority setting process: A mixed methods study
    Meeting Abstract

    Drury, A.; O'Brien, A.; O'Connell, L.; Cosgrave, S.; Hannan, M.; Smyth, C.; Fessele, K.; Harkin, M.; Rogers, L.
    International Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Examining age bias in ChatGPT responses to user questions about decision-making in advanced cancer
    Meeting Abstract

    McDarby, M.; Mroz, E.; Hahne, J.; Carpenter, B.; Parker, P.
    Innovation in Aging (2024)

    Fulltext@MSK | Save
  • Optimizing a pragmatic trial of emergency department initiated care for persons living with dementia
    Meeting Abstract

    Brody, A.; Shah, M.; Goldfeld, K.; Grudzen, C.; Chodosh, J.
    Innovation in Aging (2024)

    Fulltext@MSK | Save
  • Outcomes by comorbidities with tremelimumab and durvalumab in the phase 3 Himalaya study in unresectable hepatocellular carcinoma
    Meeting Abstract

    Rimassa, L.; Dayyani, F.; Kelley, R. K.; Sangro, B.; Chan, S. L.; McCoy, C. L.; Paskow, M. J.; Makowsky, M.; Gupta, C.; Ran, D.; more...
    Hepatology (2024)

    Fulltext@MSK | Save
  • Outcomes by baseline liver function in Emerald-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma
    Meeting Abstract

    Chan, S.; Decaens, T.; Kudo, M.; Erinjeri, J.; Lencioni, R.; Bouattour, M.; Breder, V.; Heo, J.; Mazzaferro, V.; Park, J. W.; more...
    Hepatology (2024)

    Fulltext@MSK | Save
  • Five-year overall survival and overall survival by tumor response measures from the phase 3 Himalaya study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
    Meeting Abstract

    Rimassa, L.; Chan, S.; Sangro, B.; Lau, G.; Kudo, M.; Breder, V.; Varela, M.; Crysler, O.; Bouattour, M.; Dao, T. V.; more...
    Hepatology (2024)

    Fulltext@MSK | Save
  • Non-viral etiology subgroup of the phase 3 Himalaya study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
    Meeting Abstract

    Reig, M.; Tam, V.; Sangro, B.; Archambeaud, I.; Kelley, R. K.; Chan, S.; Kudo, M.; Masi, G.; Paskow, M.; Makowsky, M.; more...
    Hepatology (2024)

    Fulltext@MSK | Save
  • Cytokine profiles associated with graft versus host disease and recent thymic emigrant T cell reconstitution after hematopoietic cell transplantation
    Meeting Abstract

    McAvoy, D.; Hosszu, K.; Thomsen, M.; Ntrivalas, E.; Klein, E.; Singh, K.; Vidal, E.; Curran, K.; Cancio, M.; Scaradavou, A.; more...
    Bone Marrow Transplantation (2024)

    Fulltext@MSK | Save
  • Multinational study assessing treatment patterns, outcomes, and healthcare resource utilization in hematopoietic stem cell transplant recipients with cytomegalovirus infection and intolerance to anti-cytomegalovirus therapies
    Meeting Abstract

    Papanicolaou, G.; Avery, R.; Fox, M. L.; Peggs, K. S.; Veloso, L.; Bo, T.; Hirji, I.; Davis, K.
    Bone Marrow Transplantation (2024)

    Fulltext@MSK | Save
  • HLA-DR + regulatory T cells are associated with the onset and severity of acute graft-versus-host disease after hematopoietic cell transplantation
    Meeting Abstract

    Hosszu, K.; McAvoy, D.; Garcia-Rosa, M.; White, C.; Thomsen, M.; Ntrivalas, E.; Klein, E.; Alsultan, A.; Mauguen, A.; Curran, K. J.; more...
    Bone Marrow Transplantation (2024)

    Fulltext@MSK | Save